Register Login

Invivyd Inc (IVVD)

(80% Positive) Invivyd, Inc. (IVVD) Announces Enrollment Update for preparing Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 8, 2026, 12:15 p.m.

    📋 Invivyd, Inc. (IVVD) - Clinical Trial Update

    Filing Date: 2026-01-08

    Accepted: 2026-01-08 07:10:43

    Event Type: Clinical Trial Update

    Event Details:

    Invivyd Inc (IVVD) Announces Clinical Trial Update Invivyd Inc (IVVD) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: preparing, even
    • Clinical Stage: clinical trial, Phase 3
    • Collaboration: RSV
    • Updated Timeline: December 2025
      • Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $
      • 2 million, representing 25% growth year
      • year and 31% growth quarter

    🔬 Clinical Development Pipeline (Invivyd, Inc.):

    Product Type Development Stage Therapeutic Area Source
    Placebo DRUG Phase PHASE3 COVID-19 ClinicalTrials.gov
    VYD2311-MD DRUG Phase PHASE3 COVID-19 ClinicalTrials.gov
    VYD2311-SD DRUG Phase PHASE3 COVID-19 ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Invivyd Inc
    • CIK: 0001832038
    • Ticker Symbol: IVVD
    • Period End Date: 2026-01-08
    • Document Type: 8-K

Search

News categories